CDK12 Changes Telling in Prostate Cancer.
A recent study established that patients with metastatic castration-resistant prostate cancer who had mutations that inactivated both CDK12 alleles also exhibited other genetic changes. Results of a small, related study suggest these genetic changes may make tumors more responsive to PD-1 inhibitors.